NCT04998851 - A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

March 29, 2024

Study Completion Date

January 13, 2025

Conditions

Multiple SclerosisClinically Isolated Syndrome

Interventions

DRUG

Ocrelizumab

Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.

Trial Locations (8)

19104

Hospital of the University of Pennsylvania, Philadelphia

28040

Hosp. Clinico San Carlos, Madrid

48867

Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, Owosso

80045

University Of Colorado, Aurora

94158

University of California San Francisco, San Francisco

60611-2987

Northwestern Memorial Hospital, Chicago

02115

Brigham and Womens Hospital, Boston

EC1M 6BQ

Queen Mary University of London, London